Table 2.
Characteristics | No. | OS | RFS | ||
---|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | ||
Age, years, ≥ 60 (vs < 60) | 117/167 | 1.232 (0.783-1.936) | 0.367 | 1.169 (0.753-1.812) | 0.487 |
Sex, male (vs female) | 126/167 | 0.974 (0.608-1.559) | 0.912 | 1.038 (0.650-1.657) | 0.876 |
CEAa, elevated (vs normal) | 30/137 | 2.087 (1.266-3.440) | 0.004 | 1.948 (1.188-3.194) | 0.008 |
CA19-9a, elevated (vs normal) | 16/137 | 2.571 (1.407-4.696) | 0.002 | 2.314 (1.272-4.211) | 0.006 |
Tumor stage, III & IV (vs I & II) | 90/167 | 5.309 (3.250-8.671) | <0.001 | 5.225 (3.252-8.393) | <0.001 |
Lymph node metastasis, presence (vs absence) | 110/167 | 4.223 (2.448-7.286) | <0.001 | 4.311 (2.536-7.328) | <0.001 |
Venous invasion, presence (vs absence) | 30/167 | 2.901 (1.827-4.607) | <0.001 | 2.789 (1.762-4.413) | <0.001 |
Tumor invasion, AGC (vs EGC) | 134/167 | 4.105 (1.959-8.601) | <0.001 | 4.429 (2.118-9.262) | <0.001 |
Histologic gradeb, WD | 11/117 | 1 | 0.039 | 1 | 0.037 |
MD | 65/117 | 2.713 (0.837-8.797) | 0.096 | 2.832 (0.874-9.170) | 0.083 |
PD | 41/117 | 4.042 (1.229-13.294) | 0.022 | 4.143 (1.262-13.602) | 0.019 |
NGF, positive (vs negative) | 68/167 | 1.943 (1.290-2.927) | 0.001 | 1.932 (1.294-2.886) | 0.001 |
HO1, positive (vs negative) | 85/167 | 2.358 (1.532-3.630) | <0.001 | 2.185 (1.438-3.321) | <0.001 |
NGF/HO1 expression, −/− | 60/167 | 1 | <0.001 | 1 | <0.001 |
−/+ or +/− | 62/167 | 2.348 (1.365-4.037) | 0.002 | 2.019 (1.203-3.389) | 0.008 |
+/+ | 45/167 | 3.489 (1.995-6.101) | <0.001 | 3.218 (1.888-5.487) | <0.001 |
Abbreviations: HR hazard ratio, EGC early gastric cancer, AGC advanced gastric cancer
aThe data for the serum levels of CEA and CA19-9 were available in 137 and 137 patients, respectively
bHistologic grading was carried in tubular and papillary type carcinomas according to the grading system of the WHO histological classification of gastric tumors